MCID: THY023
MIFTS: 65

Thymoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymoma

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to thymoma, familial and type c thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Developmental Biology. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and lung, and related phenotypes are neoplasm of the thymus and abnormality of the mediastinum

Wikipedia : 74 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 741)
# Related Disease Score Top Affiliating Genes
1 thymoma, familial 35.1 KIT HRAS
2 type c thymoma 34.7 KIT CD5
3 dendritic cell thymoma 34.5 TTN CD5 AIRE
4 epithelial malignant thymoma 34.4 TTN CD5
5 thymic carcinoma 34.1 PTPRC NKX2-1 KIT CD5
6 myasthenia gravis 33.6 TTN RYR1 IL2 CTLA4 AIRE
7 thymic epithelial tumor 33.3 KIT CD5
8 thymus cancer 33.1 TTN PTPRC NKX2-1 LCK KIT IL2
9 thyroiditis 31.3 NKX2-1 IL2 CTLA4
10 thyroid carcinoma 31.3 NKX2-1 HRAS AKT1
11 mediastinal cancer 31.1 PTPRC NKX2-1 KIT CD5
12 lymphoblastic lymphoma 31.0 PTPRC DNTT CD5
13 anemia, autoimmune hemolytic 31.0 IL2 CTLA4 CD5
14 combined t cell and b cell immunodeficiency 30.9 PTPRC IL2 CTLA4
15 pemphigus foliaceus 30.9 PPL EVPL CTLA4
16 ectopic thymus 30.8 NKX2-1 CD5
17 peripheral nervous system disease 30.8 TTN RYR1 IL2 DPYSL5 CTLA4 AKT1
18 small cell carcinoma 30.8 PTPRC NKX2-1 KIT
19 vitiligo-associated multiple autoimmune disease susceptibility 1 30.8 IL2 CTLA4 AIRE
20 neuromuscular disease 30.7 TTN RYR1 IL2 DPYSL5 CTLA4 AIRE
21 neuroendocrine carcinoma 30.7 PTPRC NKX2-1 KIT
22 lymphocytic leukemia 30.7 PTPRC IL2 DNTT CD5
23 autoimmune addison disease 30.7 CTLA4 AIRE
24 lymphoproliferative syndrome 30.6 PTPRC IL2 HRAS CTLA4 AKT1
25 nevus, epidermal 30.5 HRAS AKT3 AKT2 AKT1
26 thyroid gland follicular carcinoma 30.5 NKX2-1 HRAS AKT1
27 leukemia, acute lymphoblastic 30.5 THY1 PTPRC KIT HRAS DNTT CD5
28 acute t cell leukemia 30.5 PTPRC LCK CD5 AKT1
29 t cell deficiency 30.3 PTPRC IL2 CTLA4
30 myeloma, multiple 30.3 PTPRC KIT IL2 HRAS CTLA4 CD5
31 rhabdomyosarcoma 30.3 TTN PTPRC KIT HRAS AKT1
32 iga pemphigus 30.3 PPL EVPL
33 follicular dendritic cell sarcoma 30.3 PPL KIT EVPL
34 renal cell carcinoma, nonpapillary 30.3 NKX2-1 KIT IL2 HRAS CTLA4 AKT1
35 exanthem 30.3 KIT IL2 HRAS CTLA4 AKT1
36 neuromuscular junction disease 30.2 TTN IL2 DPYSL5 CTLA4 AIRE
37 hematologic cancer 30.2 PTPRC KIT IL2 HRAS DNTT CD5
38 leukemia, chronic lymphocytic 30.2 PTPRC LCK KIT IL2 HRAS DNTT
39 myelodysplastic syndrome 30.0 THY1 KIT IL2 HRAS DNTT AKT1
40 lymphoma, non-hodgkin, familial 30.0 THY1 PTPRC LCK IL2 DNTT CTLA4
41 sezary's disease 30.0 IL2 CTLA4 CD5
42 leukemia, chronic myeloid 29.7 PTPRC LCK KIT HRAS EVPL DNTT
43 leukemia, acute myeloid 29.3 THY1 PTPRC LCK KIT IL2 HRAS
44 spindle cell thymoma 12.4
45 cortical thymoma 12.4
46 predominantly cortical thymoma 12.4
47 invasive malignant thymoma 12.4
48 mixed type thymoma 12.4
49 encapsulated thymoma 12.3
50 thymoma type ab 12.3

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

31 (show all 29)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the thymus 31 hallmark (90%) HP:0100521
2 abnormality of the mediastinum 31 hallmark (90%) HP:0045026
3 ptosis 31 frequent (33%) HP:0000508
4 diplopia 31 frequent (33%) HP:0000651
5 dysphagia 31 frequent (33%) HP:0002015
6 fatigue 31 frequent (33%) HP:0012378
7 dyspnea 31 frequent (33%) HP:0002094
8 cough 31 frequent (33%) HP:0012735
9 chest pain 31 frequent (33%) HP:0100749
10 lymphadenopathy 31 frequent (33%) HP:0002716
11 fatigable weakness 31 frequent (33%) HP:0003473
12 interstitial pulmonary abnormality 31 frequent (33%) HP:0006530
13 arthritis 31 occasional (7.5%) HP:0001369
14 alopecia 31 occasional (7.5%) HP:0001596
15 pancytopenia 31 occasional (7.5%) HP:0001876
16 hemolytic anemia 31 occasional (7.5%) HP:0001878
17 skin rash 31 occasional (7.5%) HP:0000988
18 limitation of joint mobility 31 occasional (7.5%) HP:0001376
19 xerostomia 31 occasional (7.5%) HP:0000217
20 pericarditis 31 occasional (7.5%) HP:0001701
21 myositis 31 occasional (7.5%) HP:0100614
22 abnormality of the pleura 31 occasional (7.5%) HP:0002103
23 thyroiditis 31 occasional (7.5%) HP:0100646
24 decreased antibody level in blood 31 occasional (7.5%) HP:0004313
25 nephrotic syndrome 31 occasional (7.5%) HP:0000100
26 keratoconjunctivitis sicca 31 occasional (7.5%) HP:0001097
27 myocarditis 31 occasional (7.5%) HP:0012819
28 b lymphocytopenia 31 occasional (7.5%) HP:0010976
29 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.9 HRAS
2 Decreased viability GR00221-A-1 10.9 AKT1 AKT3 HRAS LCK AKT2 KIT
3 Decreased viability GR00221-A-2 10.9 AKT1 AKT3 HRAS LCK TTN
4 Decreased viability GR00221-A-3 10.9 AKT1 AKT3 HRAS LCK AKT2
5 Decreased viability GR00221-A-4 10.9 AKT1 AKT3 TTN AKT2
6 Decreased viability GR00301-A 10.9 AKT3 LCK AKT2 KIT
7 Decreased viability GR00342-S-1 10.9 LCK TTN
8 Decreased viability GR00342-S-3 10.9 LCK TTN AKT2
9 Decreased viability GR00402-S-2 10.9 AKT1 AKT3 HRAS LCK TTN AKT2
10 Decreased substrate adherent cell growth GR00193-A-1 10 AKT2 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 10 AKT2 AKT3 KIT LCK
12 Decreased substrate adherent cell growth GR00193-A-3 10 AKT2 AKT3 LCK
13 Decreased substrate adherent cell growth GR00193-A-4 10 KIT LCK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.92 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.92 AKT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.92 AKT2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.92 AKT3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.92 LCK
19 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.92 LCK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.92 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.92 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.92 AKT2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.92 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.92 AIRE
25 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.92 AKT3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.92 KIT
27 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.92 AKT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.92 AIRE
29 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.92 LCK
30 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.92 LCK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.92 LCK
32 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.92 LCK
33 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.92 KIT
34 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.92 AKT2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.92 AKT3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.92 AKT1 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.92 AIRE
38 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.92 AKT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.92 AKT3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.92 AKT1 AKT2 AKT3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.92 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.92 AIRE
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.92 AIRE AKT1 AKT2 AKT3 KIT LCK
44 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.92 KIT
45 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.92 KIT
46 Decreased cell migration GR00055-A-1 9.72 AKT1 AKT2 AKT3 HRAS LCK
47 Increased cell viability after pRB stimulation GR00230-A-1 9.35 AKT1 AKT2 AKT3 KIT LCK

MGI Mouse Phenotypes related to Thymoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 AIRE AKT1 AKT2 AKT3 CTLA4 DNTT
2 immune system MP:0005387 10.25 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
3 hematopoietic system MP:0005397 10.23 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
4 endocrine/exocrine gland MP:0005379 10.22 AIRE AKT1 AKT2 AKT3 CTLA4 HRAS
5 cardiovascular system MP:0005385 10.21 AKT1 AKT3 CTLA4 HRAS IL2 KIT
6 digestive/alimentary MP:0005381 10.1 AIRE CTLA4 HRAS IL2 KIT NKX2-1
7 integument MP:0010771 10.07 AKT1 AKT2 CD5 CTLA4 EVPL HRAS
8 nervous system MP:0003631 10 AIRE AKT1 AKT2 AKT3 CD5 DPYSL5
9 neoplasm MP:0002006 9.97 AIRE AKT1 AKT2 AKT3 HRAS IL2
10 normal MP:0002873 9.8 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
11 no phenotypic analysis MP:0003012 9.76 AIRE AKT2 CD5 HRAS IL2 KIT
12 respiratory system MP:0005388 9.36 AIRE AKT1 AKT2 CTLA4 HRAS IL2

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7 Anti-Infective Agents Phase 4
8 Antifungal Agents Phase 4
9 Calcineurin Inhibitors Phase 4
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
15 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
16 Cola Phase 3
17 Analgesics Phase 3
18 Liver Extracts Phase 3
19 Central Nervous System Depressants Phase 3
20 Narcotics Phase 3
21 Adjuvants, Anesthesia Phase 3
22 Anesthetics Phase 3
23 Anesthetics, General Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics, Intravenous Phase 3
26 Albumin-Bound Paclitaxel Phase 3
27 Antimitotic Agents Phase 3
28 Antineoplastic Agents, Immunological Phase 3
29 Immunologic Factors Phase 3
30 Angiogenesis Inhibitors Phase 3
31 Antibodies, Monoclonal Phase 3
32 Immunoglobulins Phase 3
33 Antibodies Phase 3
34
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
35
Pasireotide Approved Phase 2 396091-73-9 9941444
36
Melphalan Approved Phase 2 148-82-3 4053 460612
37
Busulfan Approved, Investigational Phase 2 55-98-1 2478
38
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
39
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
40
Turmeric Approved, Experimental, Investigational Phase 2
41
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
42
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
43
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
44
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
45
Sodium citrate Approved, Investigational Phase 2 68-04-2
46
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
47
nivolumab Approved Phase 2 946414-94-4
48
Nedaplatin Approved, Investigational Phase 2 95734-82-0
49
ramucirumab Approved, Investigational Phase 2 947687-13-0
50
Phenobarbital Approved, Investigational Phase 2 50-06-6 4763

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
3 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
4 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
7 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
8 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
9 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS:A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
10 A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer Terminated NCT00520975 Phase 3 Carboplatin;Paclitaxel
11 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Unknown status NCT02049047 Phase 2 Everolimus
12 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Unknown status NCT02307500 Phase 2 Regorafenib
13 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Unknown status NCT02607631 Phase 2 Pembrolizumab
14 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
15 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
16 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
17 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
18 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
19 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
20 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
21 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
22 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
23 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
24 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
25 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
26 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
27 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
28 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
29 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
30 Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) Completed NCT00641147 Phase 2 Curcumin
31 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
32 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
33 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
34 Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation Completed NCT01277757 Phase 2 Akt Inhibitor MK2206
35 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
36 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
37 A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer Completed NCT01964924 Phase 2 Akt Inhibitor GSK2141795;Trametinib
38 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
39 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
40 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
41 Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
42 Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
43 A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma Completed NCT00729586 Phase 2 Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
44 A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer Completed NCT00126503 Phase 1, Phase 2 Sorafenib Tosylate
45 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
46 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
47 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
48 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Recruiting NCT03466827 Phase 2 Selinexor
49 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
50 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

19
Thymus

MalaCards organs/tissues related to Thymoma:

40
Thymus, T Cells, Lung, Thyroid, B Cells, Breast, Bone

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 7868)
# Title Authors PMID Year
1
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. 54 61
19876913 2010
2
Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. 54 61
19747927 2010
3
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 54 61
19693092 2009
4
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 54 61
18635704 2009
5
AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia. 54 61
20046382 2009
6
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 54 61
18647207 2009
7
Early loss of mammalian target of rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic nuclear factor 1-alpha (HNF1A) function in INS-1 insulinoma cells. 54 61
18949455 2009
8
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 54 61
18728167 2008
9
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells. 54 61
18509162 2008
10
Infrequent and low AIRE expression in thymoma: difference in AIRE expression among WHO subtypes does not correlate with association of MG. 54 61
18568643 2008
11
CRMP5 antibodies in patients with small-cell lung cancer or thymoma. 54 61
17657489 2008
12
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. 54 61
18567864 2008
13
Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? 54 61
17928069 2007
14
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. 54 61
17590173 2007
15
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 54 61
17611497 2007
16
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. 54 61
17539937 2007
17
Is excitation-contraction coupling impaired in myasthenia gravis? 54 61
17307394 2007
18
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). 54 61
17334980 2007
19
Expression of p63 in thymomas and normal thymus. 54 61
17276940 2007
20
AKT1 and neurocognition in schizophrenia. 54 61
17464696 2007
21
[Thymus CT scan and thymoma associated antibodies in myasthenia gravis with thymoma]. 54 61
16995304 2006
22
Exogenous nitric oxide stimulates cell proliferation via activation of a mitogen-activated protein kinase pathway in ovine fetoplacental artery endothelial cells. 54 61
16251502 2006
23
[Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors]. 54 61
16608644 2006
24
Titin and ryanodine receptor antibodies in myasthenia gravis. 54 61
16637922 2006
25
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. 54 61
16125946 2005
26
Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. 54 61
16120143 2005
27
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. 54 61
15760917 2005
28
Analysis of cell cycle regulator proteins in encapsulated thymomas. 54 61
16033820 2005
29
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]. 54 61
15634634 2004
30
Association of AKT1 with schizophrenia confirmed in a Japanese population. 54 61
15522255 2004
31
The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. 54 61
15316806 2004
32
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. 54 61
17670226 2004
33
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model. 54 61
14688799 2004
34
Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. 54 61
14673901 2003
35
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. 54 61
14652817 2003
36
Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. 54 61
14641516 2003
37
Increased thymocyte CD4+CD8+ cells and T-cell receptor beta gene rearrangements in thymoma. 54 61
14621007 2003
38
Role of antioxidant genes for the activity of artesunate against tumor cells. 54 61
12964009 2003
39
Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. 54 61
14592894 2003
40
Myasthenia gravis in individuals over 40. 54 61
14592910 2003
41
Expression status of E-cadherin and alpha-, beta-, and gamma-catenins in thymoma. 54 61
11899204 2002
42
Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? 54 61
11706095 2001
43
[Auto-antibodies against acetylcholine receptors in myasthenia gravis]. 54 61
11688208 2001
44
[The significance of Titin antibody in diagnosing myasthenia gravis with thymoma]. 54 61
11766610 2001
45
Titin, thymoma, and myasthenia gravis. 54 61
11405799 2001
46
Interleukin-1 beta induced synthesis of protein kinase C-delta and protein kinase C-epsilon in EL4 thymoma cells: possible involvement of phosphatidylinositol 3-kinase. 54 61
11549843 2001
47
IL-2 independent transformation of a unique human T cell line, TY8-3, and its subclones by HTLV-I and -II. 54 61
11149427 2001
48
Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. 54 61
11182151 2001
49
DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences. 54 61
11764930 2001
50
The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. 54 61
11074791 2000

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIT NM_000222.2(KIT):c.1468G>A (p.Glu490Lys)SNV Pathogenic 375903 rs1057519701 4:55592144-55592144 4:54725978-54725978
2 KIT NM_000222.2(KIT):c.1657T>A (p.Tyr553Asn)SNV Pathogenic 375907 rs1057519704 4:55593591-55593591 4:54727425-54727425
3 KIT NM_000222.2(KIT):c.1730_1738del (p.Pro577_Asp579del)deletion Pathogenic 375920 rs1131692239 4:55593662-55593670 4:54727496-54727504
4 KIT NM_000222.2(KIT):c.2460T>A (p.Asp820Glu)SNV Pathogenic 375929 rs1057519711 4:55599334-55599334 4:54733168-54733168
5 KIT NM_001093772.1(KIT):c.1664_1666TTG[1] (p.Val556del)short repeat Pathogenic/Likely pathogenic 375913 rs121913685 4:55593609-55593611 4:54727443-54727445
6 KIT NM_000222.2(KIT):c.1727T>C (p.Leu576Pro)SNV Pathogenic/Likely pathogenic 375919 rs121913513 4:55593661-55593661 4:54727495-54727495
7 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
8 KIT NM_000222.2(KIT):c.1676T>C (p.Val559Ala)SNV Pathogenic/Likely pathogenic 13865 rs121913517 4:55593610-55593610 4:54727444-54727444
9 KIT NM_000222.2(KIT):c.1669T>C (p.Trp557Arg)SNV Likely pathogenic 375909 rs121913235 4:55593603-55593603 4:54727437-54727437
10 KIT NM_000222.2(KIT):c.2089C>T (p.His697Tyr)SNV Uncertain significance 375925 rs763308199 4:55595599-55595599 4:54729433-54729433

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 RYR1 PTPRC KIT IL2 HRAS AKT3
2
Show member pathways
13.49 PTPRC PPL KIT IL2 HRAS EVPL
3
Show member pathways
13.48 PTPRC PPL LCK KIT HRAS CTLA4
4
Show member pathways
13.39 TTN LCK IL2 HRAS AKT3 AKT2
5
Show member pathways
13.37 PTPRC KIT IL2 HRAS AKT3 AKT2
6
Show member pathways
13.29 PTPRC LCK IL2 HRAS AKT3 AKT2
7
Show member pathways
13.11 LCK KIT IL2 HRAS AKT3 AKT2
8
Show member pathways
13.06 KIT IL2 HRAS AKT3 AKT2 AKT1
9
Show member pathways
12.95 PTPRC LCK HRAS CTLA4 AKT3 AKT2
10
Show member pathways
12.9 KIT HRAS AKT3 AKT2 AKT1
11 12.9 KIT IL2 HRAS AKT3 AKT2 AKT1
12
Show member pathways
12.85 IL2 HRAS AKT3 AKT2 AKT1
13
Show member pathways
12.84 RYR1 HRAS AKT3 AKT2 AKT1
14 12.84 KIT HRAS AKT3 AKT2 AKT1
15
Show member pathways
12.84 KIT HRAS AKT3 AKT2 AKT1
16
Show member pathways
12.81 KIT HRAS AKT3 AKT2 AKT1
17
Show member pathways
12.76 LCK KIT HRAS AKT3 AKT2 AKT1
18
Show member pathways
12.66 IL2 HRAS AKT3 AKT2 AKT1
19
Show member pathways
12.66 PTPRC HRAS AKT3 AKT2 AKT1
20
Show member pathways
12.64 NKX2-1 HRAS AKT3 AKT2 AKT1
21 12.63 PTPRC LCK KIT IL2 CTLA4
22
Show member pathways
12.6 LCK CTLA4 AKT3 AKT2 AKT1
23
Show member pathways
12.6 PTPRC LCK IL2 HRAS AKT3 AKT2
24
Show member pathways
12.59 PTPRC LCK HRAS AKT3 AKT2 AKT1
25
Show member pathways
12.58 HRAS AKT3 AKT2 AKT1
26
Show member pathways
12.5 HRAS AKT3 AKT2 AKT1
27
Show member pathways
12.5 IL2 HRAS AKT3 AKT2 AKT1
28
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
29
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
30
Show member pathways
12.46 HRAS AKT3 AKT2 AKT1
31
Show member pathways
12.45 KIT HRAS AKT3 AKT2 AKT1
32
Show member pathways
12.42 RYR1 HRAS AKT3 AKT2 AKT1
33
Show member pathways
12.41 HRAS AKT3 AKT2 AKT1
34
Show member pathways
12.4 HRAS AKT3 AKT2 AKT1
35
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
36
Show member pathways
12.39 PTPRC LCK HRAS AKT3 AKT2 AKT1
37
Show member pathways
12.38 HRAS AKT3 AKT2 AKT1
38 12.37 HRAS AKT3 AKT2 AKT1
39
Show member pathways
12.37 IL2 HRAS AKT3 AKT2 AKT1
40
Show member pathways
12.36 HRAS AKT3 AKT2 AKT1
41
Show member pathways
12.31 HRAS AKT3 AKT2 AKT1
42
Show member pathways
12.3 PTPRC LCK IL2 HRAS CTLA4 AKT3
43 12.29 LCK IL2 HRAS AKT3 AKT2 AKT1
44
Show member pathways
12.27 HRAS AKT3 AKT2 AKT1
45
Show member pathways
12.26 PTPRC LCK HRAS AKT3 AKT2 AKT1
46
Show member pathways
12.25 HRAS AKT3 AKT2 AKT1
47
Show member pathways
12.25 IL2 HRAS AKT3 AKT2 AKT1
48
Show member pathways
12.25 LCK CTLA4 AKT3 AKT2 AKT1
49 12.24 HRAS AKT3 AKT2 AKT1
50
Show member pathways
12.22 HRAS AKT3 AKT2 AKT1

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 THY1 PTPRC KIT CTLA4 CD5

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 KIT IL2 HRAS AKT2 AKT1
2 positive regulation of gene expression GO:0010628 9.88 TTN NKX2-1 KIT HRAS AKT1
3 phosphorylation GO:0016310 9.88 TTN LCK KIT AKT3 AKT2 AKT1
4 protein phosphorylation GO:0006468 9.8 TTN LCK KIT AKT3 AKT2 AKT1
5 negative regulation of protein kinase activity GO:0006469 9.71 THY1 PTPRC AKT1
6 positive regulation of protein phosphorylation GO:0001934 9.67 IL2 HRAS AKT2 AKT1
7 release of sequestered calcium ion into cytosol GO:0051209 9.61 RYR1 PTPRC LCK
8 mammary gland epithelial cell differentiation GO:0060644 9.57 AKT2 AKT1
9 positive regulation of phospholipase C activity GO:0010863 9.56 KIT HRAS
10 negative thymic T cell selection GO:0045060 9.55 PTPRC AIRE
11 T cell receptor signaling pathway GO:0050852 9.55 THY1 PTPRC LCK HRAS CTLA4
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.52 PTPRC IL2
13 positive regulation of mitochondrial membrane potential GO:0010918 9.51 AKT2 AKT1
14 positive regulation of glucose metabolic process GO:0010907 9.49 AKT2 AKT1
15 peripheral nervous system myelin maintenance GO:0032287 9.46 AKT2 AKT1
16 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT2 AKT1
17 T cell costimulation GO:0031295 9.26 LCK CTLA4 CD5 AKT1
18 T cell differentiation GO:0030217 8.92 PTPRC LCK KIT IL2

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 TTN LCK KIT AKT3 AKT2 AKT1
2 protein kinase binding GO:0019901 9.72 TTN THY1 PTPRC LCK AKT1
3 protein binding GO:0005515 9.6 TTN THY1 RYR1 PTPRC PPL NKX2-1
4 enzyme binding GO:0019899 9.55 TTN THY1 RYR1 NKX2-1 AKT1
5 protein kinase activity GO:0004672 9.43 TTN LCK KIT AKT3 AKT2 AKT1

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....